USPTO Patent Applications - Organic Chemistry (C07D)

Pharmaceutically Acceptable Salt and Crystal Form of Tetrahydronaphthalene Derivative

USPTO published patent application US20260098027A1 for a pharmaceutically acceptable salt and crystal form of a tetrahydronaphthalene derivative, specifically covering (S)-3-(5-(4-((1-(4-((1R,2R)-6-hydroxy-2-isobutyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and its preparation method. Inventors include Lina Jia, Junran Yang, Zhenxing Du, Lin Wang, Qiyun Shao, and Jun Feng.

Bristol-Myers Squibb Hemoglobinopathy Treatment Compounds

USPTO published patent application US20260098028A1 by Bristol-Myers Squibb Company covering compounds for treatment of hemoglobinopathies. The application includes claims for pharmaceutical compositions and methods of preventing or treating these blood disorders. The A1 publication followed a September 2025 filing date with European application number 19328416.

Amgen KIF18A Kinase Inhibitor Patent Application for Cancer Treatment

USPTO published Amgen's patent application US20260098029A1 for KIF18A protein-modulating compounds intended to treat cancer and cancer-related diseases. The application discloses compounds of formula (I) with synthetic intermediates, pharmaceutical compositions, and methods of treatment. The 15 named inventors include researchers from Amgen's medicinal chemistry and oncology teams.

Deuterated Organic Compounds for Schizophrenia and Depression Treatment

The USPTO published patent application US20260098011A1 covering deuterated organic compounds of Formula I and II for modulating dopamine and serotonin neurotransmission. The compounds are directed toward treating disorders including schizophrenia and depression. The application was filed on June 11, 2025, under application number 19235237.

Tetrahydroacridinone Analogues for Malaria Treatment and Prevention

The USPTO published patent application US20260098012A1 for tetrahydroacridinone scaffold molecules exhibiting antimalarial activity against multiple Plasmodium spp. strains in erythrocytic and exoerythrocytic stages. The application, filed December 11, 2025, names 11 inventors including Dennis E. Kyle and Steven Maher and covers pharmaceutical compositions for malaria treatment and prevention.

Dextrorphan Amino Acid Ester Stereoisomer Conjugates with Improved Bioavailability

The USPTO published patent application US20260098013A1 disclosing amino acid ester conjugates of dextrorphan using diastereomerically pure amino acids to improve bioavailability. Inventors include Sven Guenther, Travis Mickle, Sanjib Bera, and Amarraj Chakraborty. The application covers pharmaceutical compositions and methods of treating diseases using these conjugates.

Ionizable Lipidoid Compositions and Therapeutic Uses Thereof

Ionizable Lipidoid Compounds for Therapeutic Agent Delivery

Crystalline Imidazole Polymorphs for Mitochondria and Cardiovascular Treatment

USPTO published patent application US20260098015A1 for crystalline polymorphic forms of 5-[(2,4-dinitrophenoxy)methyl]-1-methyl-2-nitro-1H-imidazole. The compound is directed to treating mitochondria-related disorders and cardiovascular disorders or conditions. The application was filed May 19, 2025 and names Muralikrishna DUVVURI, Donald Herbert LAMUNYON, and Micah Jeffrey BODNER as inventors.

Method and System for Fully Continuous-Flow Preparation of Nitroimidazole Antimicrobial Agent

USPTO published patent application US20260098016A1 for a fully continuous-flow method of synthesizing nitroimidazole antimicrobial agents. The method uses glyoxal aqueous solution, acetaldehyde aqueous solution, and ammonium hydroxide as raw materials through multi-step chemical reactions. Inventors include Fener Chen, Minjie Liu, Li Wan, Yajiao Zhang, Xingpeng Cai, and Zhisheng Yang. The system includes micromixers, microreactors, back pressure valves, gas-liquid separators, and online solvent switching units.

Novel Aromatic Ring Derivative Containing Amide Substitution as TYK2 Inhibitor

The USPTO has published patent application US20260098017A1 for a novel aromatic ring derivative containing amide substitution as a TYK2 inhibitor for treating inflammatory and autoimmune diseases including psoriasis, psoriatic arthritis, dermatitis, lupus, inflammatory bowel disease, and rheumatoid arthritis. The application was filed December 22, 2023, with inventors including Wenzhi Wang, Shuangyong Sun, and colleagues. The invention demonstrates therapeutic efficacy in psoriasis and asthma animal models with good druggability, stability, and safety profiles.

Bicyclic 1,4-Diazepanones and Therapeutic Uses

The USPTO published patent application US20260098018A1 disclosing bicyclic 1,4-diazepanone compounds of formula (I) and their therapeutic uses for treating diseases responsive to modulation of skeletal sarcomere contractility. The application names 15 inventors and was filed July 7, 2025 under Application No. 19261878.

NSAID Conjugate Anti-Inflammatory Compounds Via Microwave Synthesis

The USPTO published patent application US20260098019A1 for microwave-synthesized NSAID conjugate compounds containing triazolyl heterocycles. The compounds are derivatives of FDA-approved anti-inflammatory drugs such as ibuprofen and indomethacin. The application claims improved anti-inflammatory efficacy with reduced ulcerogenic effects and selective COX-2 inhibition over COX-1.

Annelated Pyridines as Steroidogenesis Inhibitors

USPTO published patent application US20260092074A1 by Hoffmann-La Roche covering annelated pyridine compounds as steroid synthetase inhibitors for pharmaceutical use. The application, filed September 25, 2023, discloses small-molecule heterocyclic compounds (C07D class) with applications in steroid hormone regulation. Inventors include Qingzhong Hu, Lina Yin, and Haiyan Li.

Novel Heterocyclic Compounds Patent Application

The USPTO published patent application US20260092073A1 by Hoffmann-La Roche Inc. for novel heterocyclic compounds with general formula I, including compositions and methods of use. The application (Filing Date: 2025-10-15) covers compounds where R1, R2, R9, A1, Rx and Ry define specific substituents. Inventors include David BON, Lea Aurelie BOUCHE, Wolfgang GUBA, and others. CPC Classification: C07D 498/04.

Substituted Indazoles IRAK4 Inhibitor Patent Application

The USPTO published patent application US20260092069A1 by inventors Terstiege, Schiesser, Xue, Chang, and Berggren for substituted indazoles as IRAK4 inhibitors with potential therapeutic utility. The application (No. 19343252) was filed September 29, 2025 and published April 2, 2026. IRAK4 inhibitors target inflammatory and autoimmune pathways.

Aldose Reductase Inhibitors for Skin Aging and Cardiovascular Disorders

USPTO published patent application US20260092072A1 by inventor Andrew WASMUTH for aldose reductase inhibitor compounds. The application covers novel pharmaceutical compositions for treating skin aging, cardiovascular disorders, renal disorders, cancer, diabetes complications, and related conditions. The filing (Application No. 19414626) was submitted December 10, 2025, and classified under CPC codes C07D 495/04 and C07H 15/26.

SMARCA2/4 Degrader Compounds and Compositions Patent

USPTO published patent application US20260092071A1 for compounds of Formula II as SMARCA2 or SMARCA4 degraders, including their pharmaceutical compositions and uses. The application (No. 19112750) was filed on September 22, 2023, with 14 inventors including Shaomeng Wang and colleagues. This is a publication of a patent application in the field of heterocyclic compounds for potential therapeutic use.

Heterocyclic JAK Inhibitors and Canine Atopic Dermatitis Treatment

The USPTO published patent application US20260092070A1 filed by Andrew Antony Calabrese and David T. Stanton for heterocyclic compounds that inhibit Janus Kinase 1 (JAK-1) enzymes. The compounds are designed for treating inflammatory disorders in non-human mammals, specifically canine atopic dermatitis. The application was filed December 2, 2025, under Application No. 19405620.

Isotopically enriched psychedelic analogs for brain disorders

The USPTO published patent application US20260092060A1 for isotopically enriched analogs of 2-bromo-LSD, LSD, ALD-52, and 1P-LSD developed by inventors Matthew Duncton and Samuel Clark. The compounds are directed toward treating neurologic and brain disorders. The application was filed on June 5, 2025, under Application No. 19228993.

Broad Spectrum Antiviral Compositions and Methods

The USPTO published patent application US20260092059A1 by Evrys Bio, LLC covering novel thiazole- and isoquinoline-containing compounds for treating broad-spectrum viral infections. The compounds demonstrated inhibition of HCMV, influenza viruses, Zika virus, BK Virus, and RSV in cell-based assays. The application (No. 19342999) was filed September 29, 2025, and published April 2, 2026.

Seven inventors file PROTAC protein degradation compounds patent

Seven inventors file PROTAC protein degradation compounds patent

Pyridine Carboxamide Compounds for Treating Medical Conditions

The USPTO published patent application US20260092062A1 for pyridine carboxamide compounds and their use in treating medical conditions. The application was filed by inventors Todd Bosanac, Nathan Oliver Fuller, Robert Owen Hughes, Guy Bemis, and Janeta Valentina Popovici Muller on September 26, 2023, and published on April 2, 2026.

Fused Bicyclic RAF Inhibitors and Methods for Use Thereof

The USPTO published patent application US20260092063A1 for fused bicyclic RAF inhibitors as potential cancer therapeutics, including colorectal cancer treatment. Inventors include Andrew Belfield, Clifford David Jones, Jean-François Margathe, and Chiara Colletto. The application was filed on 2025-05-12 under Application No. 19205876.

Heterocyclic Compounds for Treatment of Disease

USPTO published patent application US20260092064A1 for heterocyclic compounds and compositions for treating disease, filed by inventors Raju Mohan, John Nuss, and Jason Harris on May 14, 2025. The application was published April 2, 2026, covering compounds classified under CPC codes including C07D 471/04, A61K 31/41, and A61P therapeutic categories.

Crystalline Solid Forms of BET Inhibitor for Cancer Treatment

The USPTO published patent application US20260092065A1 for crystalline solid forms of BET protein inhibitors (BRD2, BRD3, BRD4, BRD-t) useful in cancer treatment. Seven inventors (Chen, Jia, Liu, Qiao, Wu, Zhou, Li) filed the application on September 23, 2025. The application claims novel solid forms, preparation methods, and intermediates for the therapeutic compound.

Novel synthetic routes for macrocyclic heterocycle manufacturing

USPTO published patent application US20260092066A1 on April 2, 2026, disclosing novel synthetic methods for preparing macrocyclic heterocycle intermediates. The application (filed June 18, 2025, Application No. 19242506) covers efficient methods for synthesizing key intermediates in the preparation of Compound (I) with broad substituent applicability.

Method for Preparing Amidines from N-(alkyl lactams) via Dehydration Catalysis

USPTO published patent application US20260092067A1 disclosing a method for preparing amidines from N-(amino-alkyl) lactams via dehydration using heterogeneous catalysts including cerium oxide, boron phosphates, zirconium compounds, and phosphotungstic acid. The application (No. 19108987) was filed September 4, 2023 and published April 2, 2026, listing inventors Nicola Vecchini and Federico Mondini. This represents a new synthetic route for amidine compounds used in pharmaceutical and fine chemical synthesis.

PRC2 Inhibitor Patent for Cancer Treatment, Forms

USPTO published patent application US20260092068A1 for physical forms of PRC2 inhibitor compounds for cancer treatment. Inventors: Mohammad AL-SAYAH and Robert Ronald MILBURN. Application filed September 13, 2023, classified under C07D 487/04 (heterocyclic compounds - organic chemistry). The patent covers the physical forms, pharmaceutical compositions, and methods of treating cancer by administering the compound.

Methods of Making Trans Isomeric Forms of G Protein-Coupled Receptor Modulators

The USPTO published patent application US20260092049A1 disclosing methods for synthesizing trans isomeric forms of G protein-coupled receptor (GPCR) modulators with high trans isomeric purity. The application names eight inventors and covers pharmaceutical compositions and synthetic routes for producing these receptor modulators. This publication establishes priority rights for the claimed invention under 35 U.S.C.

Chemokine receptor modulators and C07D heterocyclic compounds patent application

USPTO published patent application US20260092050A1 for chemokine receptor modulators and C07D heterocyclic compounds. The application discloses novel compounds for modulating chemokine receptor activity with potential therapeutic uses. Inventors include Parcharee Tivitmahaisoon, David J. Wustrow, Mikhail Zibinsky, and Omar Robles. Filing date was January 17, 2025.

Pyrimidine Compounds for Cancer Prevention Treatment

The USPTO published patent application US20260092051A1 for pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers. Inventors include In Hwan Bae, Ji Sook Kim, Jae Yul Choi, and others. The application (No. 19203828) was filed on May 9, 2025, and published on April 2, 2026. This is an informational publication with no compliance requirements.

Muscarinic M1 Receptor Compound Treats Alzheimer Disease

USPTO published patent application US20260092052A1 for a nitrogen-containing heterocyclic compound functioning as a muscarinic M1 receptor positive allosteric modulator. The compound is intended for prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, and dementia with Lewy bodies. Inventors include Masami Yamada, Shinkichi Suzuki, Takahiro Sugimoto, Minoru Nakamura, Hiroki Sakamoto, and Makoto Kamata. Application No. 19010914 was filed on January 6, 2025.

KHK Inhibitor Heterocyclic Compounds Patent Application

The USPTO published patent application US20260092053A1 for KHK (ketohexokinase) inhibitor heterocyclic compounds, filed August 22, 2025. The application includes nine inventors and covers compounds of a specified formula with variable substituents defined in the specification. The compounds are classified under multiple CPC categories including C07D 409/14, C07D 401/14, and related pharmaceutical compound classifications.

Fused Ring STAT6 Inhibitor for Atopic Dermatitis Treatment

The USPTO published patent application US20260092054A1 disclosing a fused ring compound with STAT6 inhibitory activity for treating atopic dermatitis and allergic diseases. Invented by Yoshitake Sumikawa, Issei Akahoshi, and Masaya Kato, the application (No. 19116232) was filed September 29, 2023 and published April 2, 2026. The claimed compound and pharmaceutical compositions target inflammatory conditions via STAT6 pathway inhibition.

Aromatic Acetylene Derivative, Preparation Method Therefor, And Pharmaceutical Use Thereof

USPTO published patent application US20260092055A1 by Zhejiang Hisun Pharmaceutical Co., Ltd. for aromatic acetylene derivatives useful as LpxC inhibitors for treating bacterial infections. The application covers the chemical compounds, preparation methods, and pharmaceutical compositions. Application No. 19112826 was filed September 28, 2023.

Melanocortin-4 Receptor Agonists for Obesity and Diabetes Treatment

The USPTO published patent application US20260092056A1 for melanocortin-4 receptor agonists developed by eight inventors. The compounds of Formula 1 demonstrate agonist activity against melanocortin-4 receptors and may be useful in preventing or treating obesity, diabetes, inflammation, and erectile dysfunction.

BCL-XL/BCL-2 Degraders and Uses Thereof

The USPTO published patent application US20260092057A1 for BCL-XL/BCL-2 degrader compounds and methods of using the same for treating conditions such as cancer. The application was filed on May 12, 2023, by inventors including Huijun Dong, Bin Yang, and others, and covers novel chemical compositions under CPC classifications including C07D 417/12, C07D 471/04, and related therapeutic uses.

Small Molecule Degraders and Fluorescent Probes of PXR

USPTO published patent application US20260092058A1 disclosing compounds, compositions, and methods for degrading pregnane X receptor (PXR) protein. The invention relates to decreasing adverse drug reactions associated with administration of anticancer agents, antibacterial agents, non-steroidal anti-inflammatory agents, or anticonvulsant agents. Application No. 18902844 was filed September 30, 2024.

Dual Inhibitors for Alzheimer's Disease Treatment

USPTO published patent application US20260092039A1 for dual inhibitors (soluble epoxide hydrolase and glutaminyl cyclase inhibitors) useful for Alzheimer's disease treatment. Inventors from Spain and Germany filed Application No. 19161626 on March 4, 2024, with the application published April 2, 2026. The compounds also reduce pro-inflammatory cytokines, exhibit low cytotoxicity, and have good blood-brain barrier permeability.

Cyclopropane Carboxylic Acid Synthesis Methods

The USPTO published patent application US20260092040A1 for methods of preparing substituted cyclopropane carboxylic acid compounds. Inventors Nikolaos Papaioannou, Michael Jonathan Fray, Andreas Rennhack, and Sarah Jocelyn Fink filed the application on September 20, 2023 (Application No. 19113778). The application covers synthetic routes for these chemical compounds, which have potential uses in pharmaceutical development.

Process for Preparing Fluoro-imino-dihydropyrimidine Compounds

The USPTO published patent application US20260092041A1 for Adama Makhteshim Ltd., covering a process for preparing fluoro-imino-dihydropyrimidine compounds and derivatives. The application was filed on 2025-10-08 under Application No. 19352947. Inventors include Gal Suez, Samaa Alasibi, and Yaakov Mines.

Ipconazole preparation process patent

USPTO published patent application US20260092042A1 by inventors Mittal, Kini, Mukadam, and Shelkar disclosing a process for preparing Ipconazole, a triazole fungicide used in agriculture. The application, filed September 13, 2023, and published April 2, 2026, claims a cost-effective and environmentally friendly synthesis method suitable for large-scale industrial production.

Novel Benzoxazole Derivative Comprising 4-Amino-Butanamide and Anti-Inflammatory Use

USPTO published patent application US20260092043A1 by EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION disclosing novel benzoxazole derivatives comprising 4-amino-butanamide and their anti-inflammatory pharmaceutical applications. The application (No. 19115423) was filed March 14, 2023 and published April 2, 2026.

Pyrimidine Derivative for Inflammation Treatment

USPTO published patent application US20260092044A1 by ASKA Pharmaceutical Co., Ltd. for a pyrimidine derivative with mPGES-1 inhibitory activity for treating inflammation, pain, and rheumatism. The application was filed December 8, 2025, and names Makoto Okada, Youichi Nakano, Takashi Nose, Satoshi Maeda, and Tomoaki Watanabe as inventors.

Substituted Benzofuran, Benzopyrrole, Benzothiophene, and Structurally Related Complement Inhibitors

The USPTO published patent application US20260092045A1 for substituted benzofuran, benzopyrrole, benzothiophene compounds and structurally related compounds as complement system inhibitors. The application was filed on December 8, 2025, with 11 named inventors including Pravin L. Kotian, Yarlagadda S. Babu, and Weihe Zhang. The compounds may be formulated as pharmaceuticals for treating diseases characterized by aberrant complement system activity.

Quinoline Butenamide Maleate Salts for EGFR Cancer Treatment

The USPTO published patent application US20260092046A1 covering maleate salt forms of a quinoline-based butenamide compound designed to target epidermal growth factor receptor (EGFR) family kinases for cancer treatment. Invented by Quinhong Lu and colleagues, the application discloses crystalline forms, preparation methods, and pharmaceutical compositions. The patent application was filed on May 5, 2025, and published on April 2, 2026.

CFTR Modulator Patent, Pharmaceutical Compositions, Treatment Methods

The USPTO published patent application US20260092047A1 disclosing CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) modulator compounds of Formula (I), their pharmaceutical compositions, methods of treating cystic fibrosis, and processes for making the modulators. The application also covers solid state forms of Compound 1 and salts and solvates thereof. The application was filed on May 13, 2025, with Application No. 19206359.

Quinoline cGAS Antagonist Solid Forms and Salts

The USPTO published patent application US20260092048A1 for solid forms and salts of a quinoline cGAS antagonist compound, filed by inventors Jian Qiu, Qi Wei, Heping Shi, Lijun Sun, and Zhijian Chen (Application No. 19316546, filed September 2, 2025). The application discloses the compound's cGAS antagonist properties, methods of preparation, pharmaceutical compositions, and use in medical therapy.

Hydrochloric acid salt of 5-HT2C agonist patent application

USPTO published patent application US20260091039A1 for a crystalline hydrochloric acid salt of (R)-N-(2,2-difluoroethyl)-7-methyl-1,2,3,4,6,7-hexahydro-[1,4]diazepino[6,7,1-hi]indole-8-carboxamide (a 5-HT2C agonist). The application includes pharmaceutical composition claims and methods of use. Inventor: Anthony Clyde Blackburn. Application No. 19344622.

Cannabinoid receptor 1 antagonists/inverse agonists and uses thereof

The USPTO published patent application US20260092038A1 disclosing novel cannabinoid receptor 1 (CB1) antagonists/inverse agonists for treating metabolic disorders including diabetes, dyslipidemia, cardiovascular disorders, obesity, and cancer. Invented by Marshall Morningstar, the application covers compound compositions and therapeutic uses. Filing date was September 26, 2025.